NFlection Therapeutics: Latest News, Top Stories & Analysis

WAYNE, PA — NFlection Therapeutics, Inc. recently announced that the Food and Drug Administration (FDA) has granted the company orphan drug designation for NFX-179 for the treatment of cutaneous neurofibromatosis …

Products and Services / Research

NFlection Therapeutics Announces Positive Results of NFX-179 Gel in Subjects with NF1

May 28, 2021May 27, 2021 - by MyChesCo

WAYNE, PA — NFlection Therapeutics, Inc this week announced positive results from a 28-day, Phase 2a, multicenter, randomized, double-blind, parallel-group, vehicle-controlled clinical trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics …